Donald R. Chase - 17 Aug 2026 Form 4 Insider Report for Bluejay Diagnostics, Inc. (BJDX)

Reporting relationship: Director
Issuer ticker: BJDX
Reported as of: 17 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Aug 2026, 16:15:24 UTC
Prior SEC filing: 18 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Donald R Chase

Key filing fact

Donald R. Chase filed Form 4 for Bluejay Diagnostics, Inc. (BJDX) on 18 Aug 2026.

Key facts

This page summarizes Donald R. Chase's Form 4 filing for Bluejay Diagnostics, Inc. (BJDX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 Aug 2026, 16:15.

Change

Previous filing in this sequence was filed on 18 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001247473 Primary reporting owner

CHASE DONALD R

Relationship: Director
Address: C/O BLUEJAY DIAGNOSTICS, INC., 360 MASSACHUSETTS AVENUE, SUITE 203, ACTON
Signature: /s/ Donald R Chase
Signature date: 18 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BJDX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +100,000
Change %
Price: $0.000000^*
Shares after: 100,000
Date: 17 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $2.08
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents out-of-the-money stock options that vest and become exercisable for $2.075 per share on the first anniversary of the grant date, provided, however, that the options shall not be exercisable unless and until the U.S. Food and Drug Administration shall have granted clearance or approval of the issuer's Symphony IL-6 point-of-care testing device.